Deep Dive Into Elevance Health Stock: Analyst Perspectives (7 Ratings)
Portfolio Pulse from Benzinga Insights
Elevance Health (NYSE:ELV) received seven somewhat bullish ratings from analysts, with a current average 12-month price target of $565.57, reflecting a 1.08% increase from the previous target. The company, a leading U.S. health insurer and the largest provider of Blue Cross Blue Shield branded coverage, reported a solid revenue growth rate of 6.81% and strong financial metrics including net margin, ROE, and ROA. However, its debt-to-equity ratio is higher than the industry average.
April 04, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Elevance Health received somewhat bullish ratings from analysts, with an updated average 12-month price target of $565.57. The company's strong financial performance and market position are highlighted, despite concerns over its debt-to-equity ratio.
The somewhat bullish ratings and the increase in the average price target suggest a positive outlook for Elevance Health's stock in the short term. The company's solid revenue growth, high net margin, ROE, and ROA indicate strong financial health and operational efficiency, which are likely to support its stock price. However, the high debt-to-equity ratio could be a concern for some investors, potentially moderating the positive impact.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100